Cargando…
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
BACKGROUND: Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombinant heterodimer comprising physiologically active...
Autores principales: | Leidner, Rom, Conlon, Kevin, McNeel, Douglas G, Wang-Gillam, Andrea, Gupta, Sumati, Wesolowski, Robert, Chaudhari, Monica, Hassounah, Nadia, Lee, Jong Bong, Ho Lee, Lang, O’Keeffe, Jessica A, Lewis, Nancy, Pavlakis, George N, Thompson, John A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619015/ https://www.ncbi.nlm.nih.gov/pubmed/37907221 http://dx.doi.org/10.1136/jitc-2023-007725 |
Ejemplares similares
-
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
por: Conlon, Kevin, et al.
Publicado: (2021) -
Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021) -
IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020) -
Chorzowski festiwal lepszy niż lekcje pod tablicą
Publicado: (2009) -
IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin
por: Bellón, Teresa, et al.
Publicado: (2022)